Trial Profile
An Open-Label Phase II Study of Nivolumab (BMS-936558) in Combination With 5-Azacytidine (Vidaza) or Nivolumab With Ipilimumab in Combination With 5-Azacytidine for the Treatment of Patients With Refractory/ Relapsed Acute Myeloid Leukemia and Newly Diagnosed Older AML (> 65 Years) Patients
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 16 Oct 2023
Price :
$35
*
At a glance
- Drugs Azacitidine (Primary) ; Azacitidine (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Therapeutic Use
- 10 Oct 2023 Status changed from recruiting to completed.
- 04 Apr 2023 Planned End Date changed from 30 Apr 2023 to 30 Apr 2024.
- 04 Apr 2023 Planned primary completion date changed from 30 Apr 2023 to 30 Apr 2024.